Critical Review of the Appropriate Use Criteria for Amyloid Imaging: Effect on Diagnosis and Patient Care

Overview

Journal Alzheimers Dement (Amst)

Date 2017 Jan 6

PMID 28054024

Citations 21

Authors

Liana G Apostolova

Janelle M Haider

Naira Goukasian

Gil D Rabinovici

Gael Chetelat

John M Ringman

Sarah Kremen

Joshua D Grill

Lucas Restrepo

Mario F Mendez

Daniel H Silverman

Affiliations

Soon will be listed here.

Abstract

Introduction: The utility of the Appropriate Use Criteria (AUC) for amyloid imaging is not established.

Methods: Fifty-three cognitively impaired patients with clinical F-florbetapir imaging were classified as early and late onset, as well as AUC-consistent or AUC-inconsistent. Chi-square statistics and test were used to compare demographic characteristics and clinical outcomes as appropriate.

Results: Early-onset patients were more likely to be amyloid positive. Change in diagnosis was more frequent in late-onset cases. Change in therapy was more common in early-onset cases. AUC-consistent and AUC-inconsistent cases had comparable rates of amyloid positivity. We saw no difference in the rate of treatment changes in the AUC-consistent group as opposed to the AUC-inconsistent group.

Discussion: The primary role of amyloid imaging in the early-onset group was to confirm the clinically suspected etiology, and in the late-onset group in detecting amyloid-negative cases. The rate of therapeutic changes was significantly greater in the early-onset cases.

Citing Articles

Computerized decision support is an effective approach to select memory clinic patients for amyloid-PET.

Rhodius-Meester H, van Maurik I, Collij L, van Gils A, Koikkalainen J, Tolonen A PLoS One. 2024; 19(5):e0303111.

PMID: 38768188 PMC: 11104589. DOI: 10.1371/journal.pone.0303111.

Incremental value of amyloid PET in a tertiary memory clinic setting in China.

Chen K, Wang M, Wu J, Zuo C, Huang Y, Wang W Alzheimers Dement. 2024; 20(4):2516-2525.

PMID: 38329281 PMC: 11032579. DOI: 10.1002/alz.13728.

Trajectory of clinical symptoms in relation to amyloid chronicity.

Birdsill A, Koscik R, Cody K, Jonaitis E, Cadman R, Erickson C Alzheimers Dement (Amst). 2022; 14(1):e12360.

PMID: 36187195 PMC: 9489232. DOI: 10.1002/dad2.12360.

Amyloid PET ordering practices in a memory disorders clinic.

Turk K, Vives-Rodriguez A, Schiloski K, Marin A, Wang R, Singh P Alzheimers Dement (N Y). 2022; 8(1):e12333.

PMID: 35992217 PMC: 9382692. DOI: 10.1002/trc2.12333.

[F]THK-5351 PET Patterns in Patients With Alzheimer's Disease and Negative Amyloid PET Findings.

Oh M, Oh J, Oh S, Lee S, Roh J, Kim W J Clin Neurol. 2022; 18(4):437-446.

PMID: 35796269 PMC: 9262461. DOI: 10.3988/jcn.2022.18.4.437.

References

Okamura N, Harada R, Furukawa K, Furumoto S, Tago T, Yanai K . Advances in the development of tau PET radiotracers and their clinical applications. Ageing Res Rev. 2016; 30:107-13. DOI: 10.1016/j.arr.2015.12.010. View

Dubroff J, Nasrallah I . Will PET amyloid imaging lead to overdiagnosis of Alzheimer dementia?. Acad Radiol. 2015; 22(8):988-94. DOI: 10.1016/j.acra.2015.02.005. View

Barthel H, Gertz H, Dresel S, Peters O, Bartenstein P, Buerger K . Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011; 10(5):424-35. DOI: 10.1016/S1474-4422(11)70077-1. View

Yeo J, Waddell B, Khan Z, Pal S . A systematic review and meta-analysis of (18)F-labeled amyloid imaging in Alzheimer's disease. Alzheimers Dement (Amst). 2016; 1(1):5-13. PMC: 4876886. DOI: 10.1016/j.dadm.2014.11.004. View

Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E . 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010; 68(3):319-29. DOI: 10.1002/ana.22068. View

Sabri O, Sabbagh M, Seibyl J, Barthel H, Akatsu H, Ouchi Y . Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study. Alzheimers Dement. 2015; 11(8):964-74. DOI: 10.1016/j.jalz.2015.02.004. View

Grundman M, Johnson K, Lu M, Siderowf A, Dellagnello G, Arora A . Effect of Amyloid Imaging on the Diagnosis and Management of Patients with Cognitive Decline: Impact of Appropriate Use Criteria. Dement Geriatr Cogn Disord. 2016; 41(1-2):80-92. PMC: 6625826. DOI: 10.1159/000441139. View

Ossenkoppele R, Jansen W, Rabinovici G, Knol D, van der Flier W, van Berckel B . Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA. 2015; 313(19):1939-49. PMC: 4517678. DOI: 10.1001/jama.2015.4669. View

Beach T, Monsell S, Phillips L, Kukull W . Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol. 2012; 71(4):266-73. PMC: 3331862. DOI: 10.1097/NEN.0b013e31824b211b. View

10.

Bensaidane M, Beauregard J, Poulin S, Buteau F, Guimond J, Bergeron D . Clinical Utility of Amyloid PET Imaging in the Differential Diagnosis of Atypical Dementias and Its Impact on Caregivers. J Alzheimers Dis. 2016; 52(4):1251-62. DOI: 10.3233/JAD-151180. View

11.

Clark C, Pontecorvo M, Beach T, Bedell B, Coleman R, Doraiswamy P . Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol. 2012; 11(8):669-78. DOI: 10.1016/S1474-4422(12)70142-4. View

12.

Landau S, Mintun M, Joshi A, Koeppe R, Petersen R, Aisen P . Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012; 72(4):578-86. PMC: 3786871. DOI: 10.1002/ana.23650. View

13.

Fleisher A, Chen K, Liu X, Roontiva A, Thiyyagura P, Ayutyanont N . Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol. 2011; 68(11):1404-11. DOI: 10.1001/archneurol.2011.150. View

14.

Johnson K, Minoshima S, Bohnen N, Donohoe K, Foster N, Herscovitch P . Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education. Amyloid Imaging Task Force of the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging. Alzheimers Dement. 2013; 9(4):e106-9. DOI: 10.1016/j.jalz.2013.06.001. View

15.

Ossenkoppele R, Prins N, Pijnenburg Y, Lemstra A, van der Flier W, Adriaanse S . Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimers Dement. 2012; 9(4):414-21. DOI: 10.1016/j.jalz.2012.07.003. View

16.

Johnson K, Minoshima S, Bohnen N, Donohoe K, Foster N, Herscovitch P . Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimers Dement. 2013; 9(1):e-1-16. PMC: 3733252. DOI: 10.1016/j.jalz.2013.01.002. View

17.

Clark C, Schneider J, Bedell B, Beach T, Bilker W, Mintun M . Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011; 305(3):275-83. PMC: 7041965. DOI: 10.1001/jama.2010.2008. View

18.

Klunk W, Wang Y, Huang G, Debnath M, Holt D, Mathis C . Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci. 2001; 69(13):1471-84. DOI: 10.1016/s0024-3205(01)01232-2. View

19.

Curtis C, Gamez J, Singh U, Sadowsky C, Villena T, Sabbagh M . Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol. 2015; 72(3):287-94. DOI: 10.1001/jamaneurol.2014.4144. View